esba105
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2008 (NCT00671619)
Timeline
Indications
Mechanism of action
- TNF-alphaINHIBITOR
TNF inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- esba105
- lme636
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02482129 | Phase 2 | Jul 1, 2015 | Alcon |
| NCT02365519 | Phase 2 | Mar 1, 2015 | Alcon, Novartis |
| NCT01338610 | Phase 2 | Jun 1, 2011 | Alcon |
| NCT00823173 | Phase 2 | Jan 1, 2009 | ESBATech AG |
| NCT00671619 | Phase 1 | Apr 1, 2008 | ESBATech AG |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alcon | For profit | 3 | 2 | 1 | 2011 |
| ESBATech AG | For profit | 2 | 2 | 2 | 2008 |
| Novartis | For profit | 1 | 1 | 1 | 2015 |
3 organizations
Page 1 / 1